Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial (Q48227772)

From Wikidata

Jump to navigation Jump to search

scientific article published on 2 November 2012

Language	Label	Description	Also known as
English	Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial	scientific article published on 2 November 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/22897348

Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/22897348

0 references

1 reference

based on heuristic

inferred from title

author name string

B E Strober

1

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/22897348

J M Sobell

2

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/22897348

K C Duffin

3

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/22897348

Y Bao

4

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/22897348

A Guérin

5

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/22897348

H Yang

6

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/22897348

O Goldblum

7

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/22897348

M M Okun

8

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/22897348

P M Mulani

9

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/22897348

language of work or name

0 references

publication date

2 November 2012

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/22897348

British Journal of Dermatology

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/22897348

167

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/22897348

6

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/22897348

1374-1381

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/22897348

Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Adalimumab Improves Sleep and Sleep Quality in Patients with Active Ankylosing Spondylitis

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Effect of the first infliximab infusion on sleep and alertness in patients with active rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Use of patient-reported sleep measures in clinical trials of pain treatment: a literature review and synthesis of current sleep measures and a conceptual model of sleep disturbance in pain

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Sleep disturbances in depression and the effects of antidepressants

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Sleep and depression

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Psychometric properties of the Medical Outcomes Study Sleep measure

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Obstructive sleep apnea is independently associated with insulin resistance.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

The metabolic consequences of sleep deprivation

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-alpha antagonist

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Elevated C-reactive protein in patients with obstructive sleep apnea

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Soluble TNF-alpha receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Factors affecting sleep quality in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12000

21 January 2018

Identifiers

10.1111/BJD.12000

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/22897348

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/22897348

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48227772&oldid=2192198928"